rs1010 — VAMP8 VAMP8 3'UTR Variant

Common 3'UTR variant in VAMP8 that disrupts a microRNA-96 binding site, elevating VAMP8 protein levels in platelets and increasing platelet degranulation — associated with modestly elevated myocardial infarction and noncardioembolic stroke risk

See your personal result for VAMP8

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

VAMP8 3'UTR Variant — A Platelet Degranulation Regulator Linked to Arterial Thrombosis

When a platelet is activated at a site of vascular injury, it releases a cascade of pro-aggregatory molecules from its internal storage granules — a process called degranulation11 degranulation
the release of platelet granule contents (ADP, serotonin, thromboxane A2, fibrinogen) that amplifies the coagulation response and recruits additional platelets to the growing thrombus. The molecular machinery that executes this release depends on a family of vesicle-docking proteins called SNAREs. VAMP8 (vesicle-associated membrane protein 8, also known as endobrevin) is the key v-SNARE mediating fusion of dense granules and alpha-granules with the platelet plasma membrane. Without sufficient VAMP8, granule release is impaired; with excess VAMP8, platelets become hyperreactive. The rs1010 variant sits in the 3' untranslated region of VAMP8 mRNA and appears to modulate how much of this protein your platelets produce.

The Mechanism

The 3'UTR of a gene's mRNA transcript is the regulatory tail that controls message stability, localization, and translation efficiency — particularly through binding of small RNA molecules called microRNAs22 microRNAs
20–23 nucleotide RNA molecules that bind complementary sequences in the 3'UTR of target mRNAs and suppress translation or trigger degradation. Research by Kondkar et al. identified microRNA-96 (miR-96) as a regulator of VAMP8 expression: miR-96 caused dose-dependent decreases in both VAMP8 protein and mRNA in platelet-model cell lines. The rs1010 C allele falls within or near the miR-96 binding site in the 3'UTR, and is hypothesized to alter the efficiency of this miRNA-mediated suppression — allowing more VAMP8 mRNA to persist and more VAMP8 protein to accumulate in platelet precursor cells.

Higher VAMP8 protein translates to a lower threshold for degranulation: platelets with more VAMP8 release their contents more readily when stimulated by ADP, thrombin, collagen, or other agonists. Hyperreactive platelets — those with more pronounced degranulation — are an established intermediate phenotype on the causal pathway to arterial thrombosis.

Importantly, one study (Gaussem et al. 2009) found no association between rs1010 genotype and standard in vitro platelet function assays (aggregometry, flow cytometry for activation markers), suggesting the effect may be subtle, age-dependent, or context-specific rather than universally detectable under laboratory conditions.

The Evidence

The cardiovascular association evidence comes from several independent cohorts:

Shiffman et al.33 Shiffman et al.
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol, 2008 prospectively followed 4,522 adults aged ≥65 years and found the VAMP8 rs1010 C allele associated with incident MI at a hazard ratio of 1.2 (90% CI 1.02–1.41). This placed VAMP8 among the four SNPs with the strongest evidence for cardiovascular association in that panel.

Bare et al.44 Bare et al.
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med, 2007 included rs1010 in a composite five-variant cardiovascular risk score applied to 9,129 ARIC Study participants. Those in the top genetic risk tier (carrying 4–5 high-risk alleles including VAMP8 rs1010 C) had an HR of 1.57 (95% CI 1.21–2.04, P=0.001) for incident coronary heart disease versus the low-risk group.

Luke et al.55 Luke et al.
Polymorphisms associated with noncardioembolic stroke and coronary heart disease. Cerebrovasc Dis, 2009 extended the finding to cerebrovascular events, reporting OR=1.21 (90% CI 0.99–1.49) for noncardioembolic stroke per C allele in the Vienna Stroke Registry — consistent in direction with the MI signal.

At the protein level, Kondkar et al.66 Kondkar et al.
VAMP8/endobrevin is overexpressed in hyperreactive human platelets. J Thromb Haemost, 2010 found VAMP8 mRNA 4.8-fold higher in hyperreactive versus hyporeactive platelets (P=0.0023) across 288 healthy individuals, with protein levels varying 13-fold across subjects and 2.5-fold higher in the hyperreactive group (P=0.05). rs1010 was associated with platelet reactivity in an age-dependent manner (P<0.003). The Llobet et al. 201977 Llobet et al. 2019 thrombosis study reinforced the protein-level emphasis: elevated VAMP8 protein was associated with venous thrombosis in women (OR=3.25), but the rs1010 genotype itself showed no significant association — consistent with the variant acting as a partial modulator of expression rather than a deterministic switch.

The overall evidence level is moderate: replicated association with MI and stroke in multiple cohorts, plausible and partially characterized molecular mechanism, but contradictory in vitro platelet data and effect sizes in the HR=1.2 range that are modest and do not reach genome-wide significance thresholds.

Practical Actions

Carriers of one or two C alleles should be aware of their modestly elevated arterial thrombotic risk. Platelet hyperreactivity is a targetable intermediate phenotype: dietary long-chain omega-3 fatty acids (EPA and DHA) attenuate platelet activation and thromboxane A2 synthesis through mechanisms that are independent of VAMP8 but act on the same degranulation cascade. For CC homozygotes — who carry two copies of the high-expression allele — formal assessment of platelet function and overall cardiovascular risk profile is warranted when combined with other risk factors.

Antiplatelet therapy (aspirin, clopidogrel, ticagrelor) targets multiple steps in the platelet activation pathway including SNARE-mediated degranulation; whether rs1010 status predicts differential antiplatelet response is not yet established.

Interactions

VAMP8-mediated platelet hyperreactivity is one component of a larger thrombotic risk architecture. Variants in genes governing coagulation factor levels (F5, F2), fibrinolysis (SERPINE1/PAI-1), and platelet receptor function (ITGB3, GP1BA) can compound with VAMP8-driven hyperreactivity to substantially elevate arterial thrombotic risk beyond any single variant. The age-dependent association of rs1010 with platelet reactivity (Kondkar et al.) also suggests environmental or hormonal modifiers — particularly estrogen, which modulates platelet activation — may influence how strongly this variant expresses its phenotype.

Genotype Interpretations

What each possible genotype means for this variant.

TT Standard VAMP8 Expression Normal

Reference genotype — typical platelet degranulation capacity

In the Cardiovascular Health Study (Shiffman et al. 2008), the T/T genotype represents the non-risk reference group against which C allele carriers were compared. The hazard ratio of 1.2 per C allele for MI, and OR of ~1.21 for noncardioembolic stroke (Luke et al. 2009), are derived relative to this T/T reference. Your platelet VAMP8 expression is expected to be in the lower-to-typical range, consistent with normal granule release kinetics.

CT One C Allele Intermediate

One copy of the C allele — modestly elevated platelet activation potential

The additive inheritance pattern means heterozygotes carry intermediate VAMP8 expression and an intermediate platelet reactivity profile between T/T and C/C individuals. Kondkar et al. 2010 observed the rs1010-platelet reactivity association in an age-dependent fashion, suggesting this effect may strengthen over time — potentially relevant as cardiovascular risk accumulates with age.

The Gaussem et al. 2009 study (n not specified for individual genotypes) found no significant in vitro platelet function differences by genotype, cautioning against over-interpreting the laboratory-to-clinical translation. The clinical HR of 1.2 is modest and represents one contributor among many to overall thrombotic risk.

CC Two C Alleles High Risk

Two copies of the C allele — highest VAMP8 expression and platelet activation potential

Kondkar et al. 2010 found VAMP8 protein levels vary 13-fold across individuals, with 2.5-fold higher levels in hyperreactive platelets. C/C homozygotes likely populate the upper end of this distribution. Platelet hyperreactivity defined by VAMP8 overexpression predisposes to more rapid thrombus formation at sites of coronary plaque rupture — the proximate mechanism of most MIs.

The Llobet et al. 2019 study observed that elevated VAMP8 protein (not merely the C allele genotype) associated with venous thrombosis in women (OR=3.25), reinforcing that high VAMP8 expression — the likely state in C/C homozygotes — is the functional risk driver.

The age-dependent nature of the platelet-reactivity association (Kondkar 2010) means this risk likely compounds over time. In middle-aged and older individuals, the combination of elevated VAMP8-driven platelet reactivity with progressive atherosclerosis and reduced vascular resilience amplifies the clinical relevance of this genotype.

The overall evidence is moderate: the association is replicated, the mechanism is partially characterized, but effect sizes are modest (HR ~1.2 per allele in the largest prospective study) and one controlled platelet-function study found no in vitro difference. C/C homozygosity warrants awareness and targeted monitoring rather than alarm.